Hologic (NASDAQ:HOLX) Given “Outperform” Rating at William Blair

William Blair reaffirmed their outperform rating on shares of Hologic (NASDAQ:HOLX) in a research note issued to investors on Monday morning,RTT News reports.

HOLX has been the topic of several other reports. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Mizuho cut their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a report on Monday. Finally, Raymond James boosted their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Hologic has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Stock Down 2.1 %

HOLX opened at $68.75 on Monday. Hologic has a 12 month low of $68.61 and a 12 month high of $84.67. The company has a market cap of $15.60 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $75.44 and a 200 day moving average of $78.50.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company earned $0.89 earnings per share. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, sell-side analysts expect that Hologic will post 4.28 EPS for the current year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.75% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HOLX. Choreo LLC bought a new stake in shares of Hologic during the second quarter valued at approximately $393,000. Oppenheimer & Co. Inc. raised its holdings in Hologic by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 20,275 shares of the medical equipment provider’s stock worth $1,505,000 after purchasing an additional 500 shares in the last quarter. Federated Hermes Inc. purchased a new position in Hologic during the second quarter valued at $246,000. Oppenheimer Asset Management Inc. boosted its holdings in shares of Hologic by 11.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 38,423 shares of the medical equipment provider’s stock valued at $2,853,000 after buying an additional 3,876 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in shares of Hologic by 3.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 361,271 shares of the medical equipment provider’s stock worth $26,824,000 after buying an additional 12,671 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.